nodes	percent_of_prediction	percent_of_DWPC	metapath
Vapreotide—SSTR5—pituitary gland—Graves' disease	0.131	0.286	CbGeAlD
Vapreotide—SSTR2—eye—Graves' disease	0.113	0.248	CbGeAlD
Vapreotide—SSTR2—pituitary gland—Graves' disease	0.0842	0.184	CbGeAlD
Vapreotide—TACR1—connective tissue—Graves' disease	0.0727	0.159	CbGeAlD
Vapreotide—SSTR5—GPCRs, Class A Rhodopsin-like—GPR174—Graves' disease	0.0724	0.133	CbGpPWpGaD
Vapreotide—SSTR2—GPCRs, Class A Rhodopsin-like—GPR174—Graves' disease	0.0668	0.123	CbGpPWpGaD
Vapreotide—TACR1—adipose tissue—Graves' disease	0.0557	0.122	CbGeAlD
Vapreotide—SSTR5—Peptide GPCRs—TSHR—Graves' disease	0.0418	0.077	CbGpPWpGaD
Vapreotide—SSTR2—Peptide GPCRs—TSHR—Graves' disease	0.0386	0.071	CbGpPWpGaD
Vapreotide—TACR1—Peptide GPCRs—TSHR—Graves' disease	0.0304	0.0559	CbGpPWpGaD
Vapreotide—TACR1—Spinal Cord Injury—CXCL10—Graves' disease	0.0135	0.0249	CbGpPWpGaD
Vapreotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.0132	0.0243	CbGpPWpGaD
Vapreotide—SSTR5—Peptide ligand-binding receptors—CXCL10—Graves' disease	0.0127	0.0234	CbGpPWpGaD
Vapreotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.0122	0.0224	CbGpPWpGaD
Vapreotide—SSTR2—Peptide ligand-binding receptors—CXCL10—Graves' disease	0.0117	0.0216	CbGpPWpGaD
Vapreotide—SSTR5—G alpha (i) signalling events—CXCL10—Graves' disease	0.0107	0.0197	CbGpPWpGaD
Vapreotide—SSTR5—GPCR ligand binding—TSHR—Graves' disease	0.01	0.0185	CbGpPWpGaD
Vapreotide—SSTR2—G alpha (i) signalling events—CXCL10—Graves' disease	0.00989	0.0182	CbGpPWpGaD
Vapreotide—TACR1—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.00959	0.0176	CbGpPWpGaD
Vapreotide—SSTR2—GPCR ligand binding—TSHR—Graves' disease	0.00927	0.0171	CbGpPWpGaD
Vapreotide—TACR1—Peptide ligand-binding receptors—CXCL10—Graves' disease	0.00923	0.017	CbGpPWpGaD
Vapreotide—TACR1—Spinal Cord Injury—ICAM1—Graves' disease	0.00896	0.0165	CbGpPWpGaD
Vapreotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.00852	0.0157	CbGpPWpGaD
Vapreotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.00787	0.0145	CbGpPWpGaD
Vapreotide—TACR1—GPCR ligand binding—TSHR—Graves' disease	0.0073	0.0134	CbGpPWpGaD
Vapreotide—TACR1—Spinal Cord Injury—IFNG—Graves' disease	0.00682	0.0125	CbGpPWpGaD
Vapreotide—SSTR5—GPCR ligand binding—CXCL10—Graves' disease	0.00649	0.012	CbGpPWpGaD
Vapreotide—TACR1—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.00619	0.0114	CbGpPWpGaD
Vapreotide—SSTR2—SIDS Susceptibility Pathways—IL1B—Graves' disease	0.00618	0.0114	CbGpPWpGaD
Vapreotide—TACR1—Spinal Cord Injury—IL1B—Graves' disease	0.00608	0.0112	CbGpPWpGaD
Vapreotide—SSTR2—GPCR ligand binding—CXCL10—Graves' disease	0.00599	0.011	CbGpPWpGaD
Vapreotide—SSTR5—GPCR downstream signaling—TSHR—Graves' disease	0.00568	0.0105	CbGpPWpGaD
Vapreotide—SSTR2—GPCR downstream signaling—TSHR—Graves' disease	0.00524	0.00965	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—TSHR—Graves' disease	0.00516	0.00949	CbGpPWpGaD
Vapreotide—TACR1—SIDS Susceptibility Pathways—IL1B—Graves' disease	0.00486	0.00895	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—TSHR—Graves' disease	0.00476	0.00876	CbGpPWpGaD
Vapreotide—TACR1—GPCR ligand binding—CXCL10—Graves' disease	0.00472	0.00868	CbGpPWpGaD
Vapreotide—SSTR2—SIDS Susceptibility Pathways—TNF—Graves' disease	0.00448	0.00825	CbGpPWpGaD
Vapreotide—TACR1—Spinal Cord Injury—TNF—Graves' disease	0.00441	0.00812	CbGpPWpGaD
Vapreotide—TACR1—GPCR downstream signaling—TSHR—Graves' disease	0.00412	0.00759	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—TSHR—Graves' disease	0.00375	0.0069	CbGpPWpGaD
Vapreotide—SSTR5—GPCR downstream signaling—CXCL10—Graves' disease	0.00367	0.00675	CbGpPWpGaD
Vapreotide—TACR1—SIDS Susceptibility Pathways—TNF—Graves' disease	0.00353	0.0065	CbGpPWpGaD
Vapreotide—SSTR2—GPCR downstream signaling—CXCL10—Graves' disease	0.00339	0.00623	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—CXCL10—Graves' disease	0.00333	0.00613	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—CXCL10—Graves' disease	0.00307	0.00566	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—TSHR—Graves' disease	0.00305	0.00561	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—TSHR—Graves' disease	0.00281	0.00517	CbGpPWpGaD
Vapreotide—SSTR5—GPCR downstream signaling—IL2RA—Graves' disease	0.0028	0.00516	CbGpPWpGaD
Vapreotide—TACR1—GPCR downstream signaling—CXCL10—Graves' disease	0.00267	0.00491	CbGpPWpGaD
Vapreotide—SSTR2—GPCR downstream signaling—IL2RA—Graves' disease	0.00259	0.00476	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—IL2RA—Graves' disease	0.00255	0.00469	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—CXCL10—Graves' disease	0.00242	0.00446	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—IL2RA—Graves' disease	0.00235	0.00433	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—TSHR—Graves' disease	0.00221	0.00407	CbGpPWpGaD
Vapreotide—TACR1—GPCR downstream signaling—IL2RA—Graves' disease	0.00204	0.00375	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—CXCL10—Graves' disease	0.00197	0.00362	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—IL2RA—Graves' disease	0.00185	0.00341	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—CXCL10—Graves' disease	0.00182	0.00334	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—IL2RA—Graves' disease	0.0015	0.00277	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—CXCL10—Graves' disease	0.00143	0.00263	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—IL2RA—Graves' disease	0.00139	0.00256	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—IL2RA—Graves' disease	0.00109	0.00201	CbGpPWpGaD
